A federal appeals courtroom on Tuesday upheld a lifetime ban on “Pharma bro” Martin Shkreli from working within the prescription drugs business, in addition to an order to pay as much as $64.6 million in disgorged earnings.

The ruling by a three-judge panel on the 2nd U.S. Circuit Court docket of Appeals got here almost two years after a New York federal decide slapped the ban on Shkreli for the monopolistic habits of his then-drug firm within the distribution of its medicine Daraprim.

Shkreli first gained widespread notoriety in 2015 when his firm raised the value of that life-saving drug by greater than 4,000% in a single day.

The Federal Commerce Fee and 7 states, amongst them New York and California, had sued Shkreli within the case, which alleged violations of antitrust legal guidelines in his firm stopping generic drug makers from having access to Daraprim that they wanted to conduct testing on.

The scheme allowed Shkreli and others for greater than a yr to guard the earnings they obtained from promoting Daraprim at a value of $750 per pill, in comparison with the $17.50 it beforehand bought for.

Shkreli beforehand served a jail time period for federal securities fraud and different monetary crimes not associated to his controversial value hike of Daraprim, which is used to deal with toxoplasmosis, a parasitic situation..

A lawyer for Shkreli didn’t instantly reply to a request for remark.

That is breaking information. Please test again for updates.